RESPONSE MARKERS FOR SRC INHIBITOR THERAPIES

摘要

Methods for determining whether a subject having cancer is a good candidate for a Src inhibitor therapy. For example, methods of the embodiments can comprise testing a sample from a subject to determine whether cancer cells from the subject have reduced BRAF activity and/or express a mutant BRAF protein. Methods for treating a subject having cancer with reduced BRAF kinase activity and/or that expresses a mutant BRAF protein by administering a Src inhibitor therapy are also provided.